J. Cramer

发表

Clinical and psychopharmacologic factors influencing family burden in refractory schizophrenia. The Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

R. Rosenheck, D. Charney, D. Perlick, 2000, The Journal of clinical psychiatry.

Compliance with medication regimens for mental and physical disorders.

R. Rosenheck, J. Cramer, J. Cramer, 1998, Psychiatric services.

Development and validation of a patient-based health-related quality of life questionnaire in schizophrenia: the S-QoL

C. Lançon, P. Auquier, V. Aghababian, 2003, Schizophrenia Research.

Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol.

R. Rosenheck, D. Charney, W. Henderson, 2000, The Journal of clinical psychiatry.

A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

R. Rosenheck, J. Cramer, D. Charney, 1997, The New England journal of medicine.

How long to wait for a response to clozapine: a comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia.

R. Rosenheck, J. Cramer, D. Charney, 1999, Schizophrenia bulletin.

Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

R. Rosenheck, J. Cramer, D. Charney, 1999, The American journal of psychiatry.

Enhancing medication compliance for people with serious mental illness.

R. Rosenheck, J. Cramer, J. Cramer, 1999, The Journal of nervous and mental disease.

Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

R. Rosenheck, J. Cramer, D. Charney, 1999, Archives of general psychiatry.

Interrater reliability levels of multiple clinical examiners in the evaluation of a schizophrenic patient: quality of life, level of functioning, and neuropsychological symptomatology.

R. Rosenheck, D. Cicchetti, D. Charney, 1999, The Clinical neuropsychologist.

Does participation in psychosocial treatment augment the benefit of clozapine? Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

R. Rosenheck, D. Charney, J. Tekell, 1998, Archives of general psychiatry.

Clozapine's cost effectiveness.

R. Rosenheck, D. Charney, L. Frisman, 1995, The American journal of psychiatry.

Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

R. Rosenheck, D. Charney, J. Grabowski, 1998, Health services research.